NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
- PMID: 20664472
- PMCID: PMC3100728
- DOI: 10.1097/MPA.0b013e3181ebb168
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
Abstract
Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classification and management of patients with these tumor subtypes. We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies.
Comment in
-
Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL).Pancreas. 2012 Apr;41(3):492-3. doi: 10.1097/MPA.0b013e31822a645e. Pancreas. 2012. PMID: 22415670 No abstract available.
References
-
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. - PubMed
-
- Delle Fave G, Capurso G, Milione M, et al. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol. 2005;19:659–673. - PubMed
-
- Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–1751. - PubMed
-
- Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–172. - PubMed
-
- Norton JA, Melcher ML, Gibril F, et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136:1267–1274. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical